MLchartDataset catalogue

Patent · US5882679A · A · US

Liposomes containing active agents aggregated with lipid surfactants

(11) Publication number
US5882679A
(21) Application number
US-12965498-A
(22) Filing date
1998-08-05
(30) Priority date
1997-02-06
(43) Publication date
1999-03-16
(45) Date of grant
1999-03-16
(52) CPC
  • A61K Preparations for medical, dental or toiletry purposes: 9/1271, 9/1075
(73) Assignee
UNIV DUKE
(54) Title
Liposomes containing active agents aggregated with lipid surfactants
(57) Abstract

Liposomes contain active agents which are aggregated with a lipid surfactant. The composition of the liposome membrane stabilizes the membrane against the disruptive effects of the active agent-surfactant aggregate contained therein.

Full text
View on Google Patents

Claims (31)

  1. A liposome containing an active agent, said liposome having a lipid bilayer membrane comprising vesicle-forming lipid and from about 1 mole percent to about 22 mole percent vesicle-forming lipid derivatized with hydrophilic polymer, said active agent aggregated with lipid surfactant to form micelles, said micelles entrapped within the interior space of said liposome, wherein said polymer-derivatized lipid inhibits fusion of the liposome membrane with said micelles, compared to fusion that would occur in the absence of polymer-derivatized lipid.
  2. A liposome according to claim 1, wherein said lipid surfactant aggregated with said active agent is a lysolipid.
  3. A liposome according to claim 1, wherein said lipid surfactant aggregated with said active agent is lysophosphatidylcholine.
  4. A liposome according to claim 1, wherein said hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl alcohol.
  5. A liposome according to claim 1, wherein the liposome membrane contains said polymer-derivatized lipid in a saturating amount.
  6. A liposome according to claim 1, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 10,000 daltons.
  7. A liposome according to claim 1, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 1,000 daltons.
  8. A liposome according to claim 1, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of about 750 daltons.
  9. A liposome according to claim 1, wherein said hydrophilic polymer has a cloud temperature within physiologic range.
  10. A liposome according to claim 1, wherein said active agent is a pharmacologically active agent, a diagnostic agent, or a nutritional agent.
  11. A liposome according to claim 1, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, immunosuppressive agents, antibiotic agents, and anti-infective agents.
  12. A liposome according to claim 1, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisolone, and ibuprofen.
  13. A composition containing a plurality of liposomes according to claim 1.
  14. A liposome containing an active agent, said liposome having a lipid bilayer membrane comprising vesicle-forming lipid and from about 1 mole percent to about 22 mole percent vesicle-forming lipid derivatized with polyethylene glycol, said active agent aggregated with lipid surfactant to form micelles, said micelles entrapped within the interior space of said liposome, wherein said polyethyleneglycol-derivatized lipid inhibits fusion of the liposome membrane with said micelles, compared to fusion that would occur in the absence of polyethyleneglycol-derivatized lipid.
  15. A liposome according to claim 14, wherein said polyethylene glycol has a molecular weight of between about 300 daltons and about 10,000 daltons.
  16. A liposome according to claim 14, wherein said polyethylene glycol has a molecular weight of about 750 daltons.
  17. A liposome according to claim 14 wherein said active agent is a pharmacologically active agent, a diagnostic agent, or a nutritional agent.
  18. A liposome according to claim 14, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, immunosuppressive agents, antibiotic agents, and anti-infective agents.
  19. A liposome according to claim 14, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisolone, camptothecin and ibuprofen.
  20. A composition containing a plurality of liposomes according to claim 14.
  21. A liposome having a lipid bilayer membrane comprising a vesicle-forming lipid and from 1 mole percent to 22 mole percent vesicle-forming lipid derivatized with polyethylene glycol, said polyethylene glycol having a molecular weight of about 750 daltons, and containing a micellar preparation of paclitaxel entrapped within the interior liposomal space.
  22. A method for preparing a liposome comprising: (a) preparing a lipid film containing vesicle-forming lipid and vesicle-forming lipid derivatized with hydrophilic polymer; b) obtaining a micellar preparation of an active agent aggregated with lipid surfactant; and c) hydrating said lipid film with said micellar preparation of active agent, to produce a liposome having a lipid bilayer membrane comprising vesicle-forming lipids and from about 1 mole percent to about 22 mole percent vesicle-forming lipids derivatized with a hydrophilic polymer.
  23. A method according to claim 22, wherein said hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl alcohol.
  24. A method according to claim 22, wherein the liposome membrane contains said polymer-derivatized lipid in a saturating amount.
  25. A method according to claim 22, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 10,000 daltons.
  26. A method according to claim 22, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 1,000 daltons.
  27. A method according to claim 22, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of about 750 daltons.
  28. A method according to claim 22, wherein said hydrophilic polymer has a cloud temperature within physiologic range.
  29. A method according to claim 22, wherein said active agent is a pharmacologically active agent, a diagnostic agent, or a nutritional agent.
  30. A method according to claim 22, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, immunosuppressive agents, antibiotic agents, and anti-infective agents.
  31. A method according to claim 22, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisolone, and ibuprofen.

Citations (36)

  • US4489056A
  • US4544545A
  • US4551288A
  • US4737323A
  • US4752425A
  • US4756910A
  • US4762915A
  • US4837028A
  • US4839111A
  • US4876094A
  • US4900556A
  • US4906477A
  • US4920016A
  • US4921757A
  • US5013556A
  • US5023086A
  • US5160669A
  • US5213804A
  • US5225212A
  • US5356633A
  • US5395619A
  • US5415869A
  • US5527528A
  • US5534241A
  • US5534499A
  • US5622498A
  • US5628936A
  • US5643600A
  • WO9105546A1
  • WO9203123A1
  • WO9319738A1
  • WO9320800A1
  • WO9421235A1
  • WO9426251A1
  • WO9614057A1
  • WO9625147A1
Record as JSON
{
  "publication_number": "US5882679A",
  "country": "US",
  "kind": "A",
  "title": "Liposomes containing active agents aggregated with lipid surfactants",
  "abstract": "Liposomes contain active agents which are aggregated with a lipid surfactant. The composition of the liposome membrane stabilizes the membrane against the disruptive effects of the active agent-surfactant aggregate contained therein.",
  "claims": [
    "1. A liposome containing an active agent, said liposome having a lipid bilayer membrane comprising vesicle-forming lipid and from about 1 mole percent to about 22 mole percent vesicle-forming lipid derivatized with hydrophilic polymer, said active agent aggregated with lipid surfactant to form micelles, said micelles entrapped within the interior space of said liposome, wherein said polymer-derivatized lipid inhibits fusion of the liposome membrane with said micelles, compared to fusion that would occur in the absence of polymer-derivatized lipid.",
    "2. A liposome according to claim 1, wherein said lipid surfactant aggregated with said active agent is a lysolipid.",
    "3. A liposome according to claim 1, wherein said lipid surfactant aggregated with said active agent is lysophosphatidylcholine.",
    "4. A liposome according to claim 1, wherein said hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl alcohol.",
    "5. A liposome according to claim 1, wherein the liposome membrane contains said polymer-derivatized lipid in a saturating amount.",
    "6. A liposome according to claim 1, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 10,000 daltons.",
    "7. A liposome according to claim 1, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 1,000 daltons.",
    "8. A liposome according to claim 1, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of about 750 daltons.",
    "9. A liposome according to claim 1, wherein said hydrophilic polymer has a cloud temperature within physiologic range.",
    "10. A liposome according to claim 1, wherein said active agent is a pharmacologically active agent, a diagnostic agent, or a nutritional agent.",
    "11. A liposome according to claim 1, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, immunosuppressive agents, antibiotic agents, and anti-infective agents.",
    "12. A liposome according to claim 1, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisolone, and ibuprofen.",
    "13. A composition containing a plurality of liposomes according to claim 1.",
    "14. A liposome containing an active agent, said liposome having a lipid bilayer membrane comprising vesicle-forming lipid and from about 1 mole percent to about 22 mole percent vesicle-forming lipid derivatized with polyethylene glycol, said active agent aggregated with lipid surfactant to form micelles, said micelles entrapped within the interior space of said liposome, wherein said polyethyleneglycol-derivatized lipid inhibits fusion of the liposome membrane with said micelles, compared to fusion that would occur in the absence of polyethyleneglycol-derivatized lipid.",
    "15. A liposome according to claim 14, wherein said polyethylene glycol has a molecular weight of between about 300 daltons and about 10,000 daltons.",
    "16. A liposome according to claim 14, wherein said polyethylene glycol has a molecular weight of about 750 daltons.",
    "17. A liposome according to claim 14 wherein said active agent is a pharmacologically active agent, a diagnostic agent, or a nutritional agent.",
    "18. A liposome according to claim 14, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, immunosuppressive agents, antibiotic agents, and anti-infective agents.",
    "19. A liposome according to claim 14, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisolone, camptothecin and ibuprofen.",
    "20. A composition containing a plurality of liposomes according to claim 14.",
    "21. A liposome having a lipid bilayer membrane comprising a vesicle-forming lipid and from 1 mole percent to 22 mole percent vesicle-forming lipid derivatized with polyethylene glycol, said polyethylene glycol having a molecular weight of about 750 daltons, and containing a micellar preparation of paclitaxel entrapped within the interior liposomal space.",
    "22. A method for preparing a liposome comprising: (a) preparing a lipid film containing vesicle-forming lipid and vesicle-forming lipid derivatized with hydrophilic polymer; b) obtaining a micellar preparation of an active agent aggregated with lipid surfactant; and c) hydrating said lipid film with said micellar preparation of active agent, to produce a liposome having a lipid bilayer membrane comprising vesicle-forming lipids and from about 1 mole percent to about 22 mole percent vesicle-forming lipids derivatized with a hydrophilic polymer.",
    "23. A method according to claim 22, wherein said hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl alcohol.",
    "24. A method according to claim 22, wherein the liposome membrane contains said polymer-derivatized lipid in a saturating amount.",
    "25. A method according to claim 22, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 10,000 daltons.",
    "26. A method according to claim 22, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of between about 300 daltons and about 1,000 daltons.",
    "27. A method according to claim 22, wherein said hydrophilic polymer is polyethylene glycol having a molecular weight of about 750 daltons.",
    "28. A method according to claim 22, wherein said hydrophilic polymer has a cloud temperature within physiologic range.",
    "29. A method according to claim 22, wherein said active agent is a pharmacologically active agent, a diagnostic agent, or a nutritional agent.",
    "30. A method according to claim 22, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, immunosuppressive agents, antibiotic agents, and anti-infective agents.",
    "31. A method according to claim 22, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisolone, and ibuprofen."
  ],
  "cpc": [
    "A61K 9/1271",
    "A61K 9/1075"
  ],
  "assignees": [
    "UNIV DUKE"
  ],
  "filing_date": "1998-08-05",
  "publication_date": "1999-03-16",
  "grant_date": "1999-03-16",
  "priority_date": "1997-02-06",
  "application_number": "US-12965498-A",
  "family_id": "25164667",
  "citations": [
    "US4489056A",
    "US4544545A",
    "US4551288A",
    "US4737323A",
    "US4752425A",
    "US4756910A",
    "US4762915A",
    "US4837028A",
    "US4839111A",
    "US4876094A",
    "US4900556A",
    "US4906477A",
    "US4920016A",
    "US4921757A",
    "US5013556A",
    "US5023086A",
    "US5160669A",
    "US5213804A",
    "US5225212A",
    "US5356633A",
    "US5395619A",
    "US5415869A",
    "US5527528A",
    "US5534241A",
    "US5534499A",
    "US5622498A",
    "US5628936A",
    "US5643600A",
    "WO9105546A1",
    "WO9203123A1",
    "WO9319738A1",
    "WO9320800A1",
    "WO9421235A1",
    "WO9426251A1",
    "WO9614057A1",
    "WO9625147A1"
  ]
}

Record 3,716 of 5,000 in Patents full text (MLC-0201). Request the full dataset.